A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
Year: 2022
Type: article
Abstract: Breast cancer (BC) is a powerful example of the intra- and interpatient heterogeneity of tumours; thus, there remain several grey areas in BC treatment approaches. This is especially true for advanced/metastatic disease (mBC) [ 1 , 2 , 3 ]. Organoid cultures are suitable models for studying the histological complexity and genetic heterogeneity of parental tumours and can be used to assess treatment strategies for challenging diseases such as mBC. Here, we report a proof-of-concept test case using organoid cultures from metastatic BC specimens to rapidly test drug sensitivity and molecular-lesion-driven treatments. Based on the relevant impact of PIK3CA gene mutations on breast cancer progression and resistance to therapy [ 4 ], we assessed the efficacy of alpelisib (BYL719; Novartis Pharma AG, Basel, Switzerland), a specific PI3K-α inhibitor, on organoid cultures derived from multisite mBC samples carrying specific PIK3CA gene mutations.
Source: Molecular Cancer
Authors: Sara Donzelli, Mario Cioce, Andrea Sacconi, Francesca Zanconato, Theodora Daralioti, Frauke Goeman, Giulia Orlandi, Simona Di Martino, Vito Michele Fazio, Gabriele Alessandrini, Stefano Telera, Mariantonia Carosi, Gennaro Ciliberto, Claudio Botti, Sabrina Strano, Stefano Piccolo, Giovanni Blandino
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,690
Award: G5914622547
OpenAlex ID: W4286471003
